ArticleCancer chemotherapy and pharmacology2022

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.

Wenyuan Xiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.